The Future of Peptide Therapy: What Works, What Doesn't, & What's Coming Next

About this video

Yurth contrasts an overly permissive United States peptide market, which she calls a wild west, with more restrictive access in the United Kingdom, arguing for a middle ground where trained clinicians can use peptides judiciously. She says peptides work as selective tools on cellular pathways, so matching the right peptide to the right pathway, timing, and lab picture matters more than collecting products. The conversation covers FDA restrictions driving black-market demand, receptor down-regulation and cycling considerations for growth-related peptides versus others, and cost and injection fatigue as real limits. Looking ahead, Yurth predicts a smaller set of validated peptides, wider use of repurposed drugs, and AI helping clinicians map pathway targets.

Key takeaways

• Peptide use should be pathway-driven and clinician-guided, not trend-driven
• Over-restriction and under-regulation both create risks, in Yurth’s framing
• Some peptide classes need cycling in her model; others she treats differently
• Cost and treatment fatigue are legitimate reasons to limit a protocol
• Replace what is lost with age before adding exotic interventions

Episode details: published August 24, 2026 · 1.2K views · 52:32 long. Summary written by Self Growth Videos from the episode itself. The longevity and peptide concepts described are Dr. Elizabeth Yurth’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Dr. Yurth is co-founder and Chief Medical Officer of the Boulder Longevity Institute, a clinic, and BLI Academy sells clinician education.

← Previous: The Female Longevity Blueprint · Next: Retatrutide Is Real. What’s Being Sold to You Isn’t. →

All Dr. Elizabeth Yurth videos · Dr. Elizabeth Yurth profile · Boulder Longevity Institute (official site)